Fiscal Fitness Continuum HHN Daily Video Podcasts Generations Diabetes Gatefolds Whitepapers Most Wired

This six-part series explores issues and challenges facing hospitals in their quest to control hospital-acquired infections. It is sponsored in part by a grant from Ortho-McNeil, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Part 1: The Bacterial-Resistance Crisis
Bacteria that can survive a previously effective antibiotic are a major public health threat. Overuse of antibiotics has contributed to the problem, and few new drugs are in development.

Part 2: The Cost of Resistance
Hospital-acquired infections too often are viewed as a by-product of care, the result of treating older, sicker patients, and increasing use of more invasive treatments.


Part 3: Health Care-Associated Infections
Health care-associated infections, which patients acquire while being treated for other conditions, require specific antibiotic therapy. Failure to identify the source of the infection increases the risk of mortality.

Part 4:The Clinician Perspective
Bacterial resistance has a wide-ranging impact on clinical practice. There are implications regarding the types of treatment available for infectious diseases, the effectiveness of these treatments and the cost of care.


Part 5: The C-Suite Perspective
An outbreak of methicillin-resistant Staphylococcus aureus (MRSA) at a neonatal intensive care unit prompted one hospital CEO to take a stand against hospital-acquired infections. In 2004, 18 infants were either infected or colonized with MRSA at a Novant Health hospital.

Part 6: Anti-Microbial Stewardship
Addressing antimicrobial resistance in hospitals requires a multifaceted approach. Hospitals have a long history of infection control programs designed to prevent the occurrence and transmission of infections.